Ultragenyx Pharmaceutical Stock Downgraded Amid Analyst Concerns
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its stock downgraded by Royal Bank Of Canada from a 'moderate buy' rating to a 'hold' rating on Thursday, according to Zacks. This downgrade is part of a broader trend in which several research analysts have reevaluated their views on the company's potential.
In addition to the downgrade from Royal Bank Of Canada, William Blair cut its rating for Ultragenyx Pharmaceutical from an 'outperform' rating to a 'market perform' rating. Cantor Fitzgerald decreased its price target on the stock from $103.00 to $33.00 and set an 'overweight' rating.
JPMorgan Chase & Co. lowered its rating for Ultragenyx Pharmaceutical from an 'overweight' rating to a 'neutral' rating, also decreasing its price objective for the stock from $80.00 to $36.00. Guggenheim dropped its price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a 'buy' rating.